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Background-—Plaque erosion is responsible for 25% to 40% of patients with acute coronary syndromes (ACS). Recent studies
suggest that anti-thrombotic therapy without stenting may be an option for this subset of patients. Currently, however, an invasive
procedure is required to make a diagnosis of plaque erosion. The aim of this study was to identify clinical or laboratory predictors
of plaque erosion in patients with ACS to enable a diagnosis of erosion without additional invasive procedures.
Methods and Results-—Patients with ACS who underwent optical coherence tomography imaging were selected from 11
institutions in 6 countries. The patients were classified into plaque rupture, plaque erosion, or calcified plaque, and predictors were
identified using multivariable logistic modeling. Among 1241 patients with ACS, 477 (38.4%) patients were found to have plaque
erosion. Plaque erosion was more frequent in non–ST-segment elevation-ACS than in ST-segment–elevation myocardial infarction
(47.9% versus 29.8%, P=0.0002). Multivariable logistic regression models showed 5 independent parameters associated with
plaque erosion: age <68 years, anterior ischemia, no diabetes mellitus, hemoglobin >15.0 g/dL, and normal renal function. When
all 5 parameters are present in a patient with non–ST-segment elevation-ACS, the probability of plaque erosion increased to 73.1%.
Conclusions-—Clinical and laboratory parameters associatedwith plaque erosion are explored in this retrospective registry study. These
parametersmay beuseful to identify the subset ofACSpatientswith plaqueerosionandguide themtoconservativemanagementwithout
invasive procedures. The results of this exploratory analysis need to be confirmed in large scale prospective clinical studies.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identifier: NCT03479723. ( J Am Heart Assoc. 2019;8:
e012322. DOI: 10.1161/JAHA.119.012322.)
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P laque erosion is reported to be responsible for about 25%to 40% of patients with acute coronary syndromes
(ACS).1–3 Current guidelines recommend early invasive
strategy for all ACS patients except for the low-risk
subgroups4,5 and coronary stents are implanted in the
majority of the cases. Recent studies reported that ACS
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patients with plaque erosion might be treated conservatively
without stenting.6–8 In these studies, a diagnosis of plaque
erosion was made by intracoronary optical coherence
tomography (OCT). If the patients with plaque erosion are
identified by demographic information or by simple laboratory
tests, invasive procedures and procedure-related complica-
tions may be avoided, and healthcare costs may be signifi-
cantly reduced. However, demographic characteristics
specific for the patients with plaque erosion are unknown.
Although several groups published reports on plaque ero-
sion,9–11 the study population in each report was too small or
unbalanced to identify comprehensive characteristics associ-
ated with plaque erosion. The aim of the current study was to
identify the predictors for plaque erosion in patients with ACS.
Methods
The data that support the findings of this study are available
from the corresponding author upon reasonable request.
Study Design and Participants
A new multi-center longitudinal international registry was
created for this study from 11 institutions in 6 countries
(Table S1) (Identification of Predictors for Coronary Plaque
Erosion in Patients with Acute Coronary Syndrome study,
http://www.clinicaltrials.gov: NCT03479723). Consecutive
patients with ACS who had OCT imaging of the culprit lesion
were eligible for the study. We included only patients who had
undergone an OCT procedure, therefore this study was not
“all-comer” registry. ACS includes ST-segment–elevation
myocardial infarction (STEMI) and non–ST-segment–elevation
ACS (NSTE-ACS) which included non–ST-segment–elevation
myocardial infarction (NSTEMI) and unstable angina pectoris.
The data set consists of previously published1,2,9,10 (n=695)
and unpublished (n=1004) patients. Among 1699 patients,
458 patients were excluded and 1241 patients were included
in the final cross-sectional analysis (Figure S1). The protocol
was approved by the institutional review board at each site
and written informed consent was obtained from all patients
before enrollment. The definitions are described in Data S1.
Demographic data, medical history, laboratory data at admis-
sion, percutaneous coronary intervention procedure data,
post-percutaneous coronary intervention biomarkers, and in-
hospital death were collected. OCT imaging and angiographic
imaging at index procedure were also collected. All images
were de-identified, digitally stored, and sent to Massachusetts
General Hospital (Boston, MA, USA), where analysis was
performed.
OCT Image Acquisition
A frequency-domain OCT system (C7/C8 ILUMIEN OCT
Intravascular Imaging Systems, St. Jude Medical, St. Paul,
Minnesota) or a time-domain OCT system (M2/M3 Cardiology
Imaging System, St. Jude Medical, Westford, Massachusetts)
was used in this study. The detailed technique of intracoro-
nary OCT imaging was described in the previous report.12
OCT Analysis
The methods of OCT analysis are summarized in Data S1.
Underlying plaque type in the culprit lesion was categorized
into 3 groups using the previously established OCT criteria;
plaque rupture, plaque erosion, calcified plaque (Figure 1A
through 1C). Plaque rupture was defined by the presence of
fibrous cap discontinuity with a communication between the
lumen and the inner core of plaque or with a cavity formation
within the plaque (Figure 1A).13,14 Plaque erosion was
identified by the presence of the attached thrombus overlying
an intact and visualized plaque, luminal surface irregularity at
the culprit lesion in the absence of thrombus, or attenuation
of the underlying plaque by thrombus without superficial lipid
or calcification immediately proximal or distal to the site of
thrombus (Figure 1B).1,2,11 Calcified plaque was defined by
the presence of superficial substantive calcium at the culprit
site without evidence of ruptured lipid plaque (Figure 1C).1,2
Culprit lesions that did not satisfy these criteria were
classified as others. Tissue characterization of underlying
plaque was performed using the previously established
criteria.15,16 Plaques were classified into 2 categories: (1)
Fibrous plaque (homogeneous and high-backscattering
Clinical Perspective
What Is New?
• Five parameters associated with plaque erosion have been
identified: age <68 years, anterior ischemia, no diabetes
mellitus, hemoglobin >15.0 g/dL, and normal renal func-
tion.
• These parameters indicate that plaque erosion may have
different pathophysiology: “non-traditional” factors including
abnormal local fluid dynamics, rather than the traditional
vascular inflammation, may play an important role.
What Are the Clinical Implications?
• If these parameters are proven to be predictive of erosion in
prospective studies, a subset of acute coronary syndromes
patients with high probability of plaque erosion may be
easily identified.
• This subset of patients may be managed conservatively with
anti-thrombotic therapy without invasive procedures.
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region) or (2) Lipid plaque (low signal region with a diffuse
border). Lipid-rich plaque was defined as a plaque with lipid
arc >90°. For each lipid plaque, the thinnest fibrous cap
thickness and the maximal lipid arc were measured. A thin-
cap fibroatheroma was defined as plaque with a lipid arc >90°
and the thinnest part of the fibrous cap <65 lm. Macrophage
accumulations were defined as signal-rich, distinct, or
confluent punctuate regions with heterogeneous backward
shadows. Calcification was recorded as well-delineated, low
backscattering heterogeneous regions. Minimal flow area was
also measured for each lesion.
Angiographic Analysis
Coronary angiograms were analyzed with the Cardiovascular
Angiography Analysis System (Pie Medical Imaging B.V.,
Maastricht, The Netherlands). The reference diameter, min-
imum lumen diameter, diameter stenosis, area stenosis, and
lesion length were measured. Thrombolysis in Myocardial
Infarction flow grade was also evaluated for the culprit
vessel.
Statistical Analysis
Categorical outcomes were presented as counts and propor-
tions (%). Continuous outcomes were expressed as
meanSD. For overall between-group comparisons, 1-way
analysis of variance or Kruskal–Wallis test was applied for
continuous outcomes and Chi-square or Fisher exact test for
categorical outcomes was applied. Then post-hoc compar-
isons with controlling type-1 error by using Bonferroni
correction were performed if the overall test was significant
with P<0.05. To identify the parameters associated with
plaque erosion, univariable and multivariable logistic regres-
sion models were applied using variables that can be readily
obtained in the emergency department (age, sex, medical
history, medication at admission, location of ischemia, simple
laboratory test (white blood cell count, hemoglobin, creatine
Figure 1. Optical coherence tomography images of 3 plaque pathologies. A, Plaque rupture was defined
by the presence of fibrous cap discontinuity with a communication between the lumen and the inner core of
a plaque or with a cavity formation within the plaque. B, Plaque erosion was defined as a culprit plaque with
an intact fibrous cap with or without attached thrombus. C, Calcified plaque was defined by the presence of
superficial substantive calcium at the culprit site without evidence of ruptured lipid plaque. Others include
spontaneous coronary artery dissection, microvascular disease, spasm, Takotsubo cardiomyopathy,
myocardial infarction with non-obstructive coronary arteries, etc. MINOCA indicates myocardial infarction
with non-obstructive coronary arteries; SCAD, spontaneous coronary artery dissection.
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phosphokinase) and renal function (normal renal function was
defined as no history of chronic kidney disease and estimated
glomerular filtration rate (eGFR) >60 mL/min at admission).
Age and hemoglobin cut-off were determined using Youden
index. Variables with a P<0.10 in the univariate test were
entered into the multivariable modeling. All statistical analy-
ses were performed using JMP PRO 13.0 (SAS Institute Inc,
Cary, NC).
Results
Among 1241 patients, 607 patients (48.9%) were classified as
plaque rupture, 477 patients (38.4%) as plaque erosion, and
157 patients (12.7%) as calcified plaque. In 648 STEMI
patients, 385 (59.4%) patients had plaque rupture and 193
(29.8%) patients had plaque erosion. In 593 NSTE-ACS
patients, 222 (37.4%) patients had plaque rupture and 284
(47.9%) patients had plaque erosion. Inter-observer and intra-
observer variability were assessed by the evaluation of all
images by 2 independent observers and by the same observer
at 2 separate time points, respectively. The intra-observer
Kappa coefficients for plaque rupture, plaque erosion, and
calcified plaque were 0.902, 0.922, 0.934, respectively. The
inter-observer Kappa coefficients for plaque rupture, plaque
erosion, and calcified plaque were 0.878, 0.895, 0.935,
respectively. Plaque erosion was significantly more frequent in
NSTE-ACS than in STEMI (47.9% versus 29.8%, P<0.0002)
(Figure 2).
Patients Characteristics
Baseline characteristics of each group are summarized in
Table 1 and Table S2. Compared with the non-erosion group,
the plaque erosion group was younger and more frequently
presented with NSTE-ACS. Hypertension, diabetes mellitus,
and chronic kidney disease were significantly less frequent in
the plaque erosion group. The plaque erosion group also had
higher levels of hemoglobin, lower levels of inflammatory
markers (high-sensitivity C-reactive protein and white blood
cell count), and a better lipid profile. The calcified plaque
group was older and had a higher prevalence of hypertension,
diabetes mellitus, and chronic kidney disease, compared with
the other groups. The patients in the calcified plaque group
were on more medications on admission. Plaque erosion was
located more frequently in the left anterior descending artery
than in the right coronary artery (56.6% versus 28.5%),
whereas plaque rupture was located equally in the left
anterior descending and the right coronary artery (45.8%
versus 40.5%). Angiographic and OCT analysis consistently
showed plaque erosion patients had less complex and less
vulnerable lesions, compared with patients with non-erosion.
Procedural detail, clinical course, and in-hospital out-
come are shown in Table S3. Thrombectomy and stenting
were more frequently performed in the plaque rupture
group than in the plaque erosion group. There was no
significant difference in in-hospital outcome between the
plaque erosion and the non-erosion group except
lower level of post-procedure peak creatine phosphokinase
in the erosion group (12641901 versus 19732332,
P<0.001).
STEMI and NSTE-ACS in Plaque Erosion
When the erosion patients were divided based on clinical
presentation, those with STEMI were more frequently smok-
ers, had higher levels of serum low-density lipoproteins, and
were on fewer medications (aspirin, P2Y12 inhibitors, statin,
angiotensin-converting enzyme inhibitor/ARB, b-blocker) on
admission than those with NSTE-ACS (Table S4).
Predictors of Plaque Erosion
Age cut-off <68 years, hemoglobin cut-off <15.0 g/dL were
determined to maximize the area under the receiver operating
characteristic (ROC) curve. As shown in Table 2, age <68
years (odds ratio [OR]: 1.56, 95% CI; 1.16–2.09, P=0.003),
anterior ischemia (OR: 1.41, 95% CI: 1.06–1.86, P=0.02), no
diabetes mellitus (OR: 1.47, 95% CI: 1.08–2.01, P=0.01),
hemoglobin >15.0 g/dL (OR: 1.48, 95% CI: 1.09–2.01,
P=0.01), and normal renal function (OR: 1.97, 95% CI:
















Figure 2. Prevalence of plaque rupture, erosion, and calcified
plaque in ST-segment–elevation myocardial infarction and non–
ST-segment–elevation acute coronary syndrome. Among 1241
patients, 648 presented with ST-segment–elevation myocardial
infarction and 593 with non–ST-segment–elevation acute coro-
nary syndrome. The prevalence of plaque rupture, plaque erosion,
and calcified plaque was 59.4%, 29.8%, and 10.8% in ST-
segment–elevation myocardial infarction; 37.4%, 47.9%, and
14.7% in non–ST-segment–elevation acute coronary syndrome.
The prevalence of plaque erosion was significantly higher in non–
ST-segment–elevation acute coronary syndrome than in ST-
segment–elevation myocardial infarction patients (47.9% vs
29.8%, P=0.0002). NSTE-ACS indicates non–ST-segment–eleva-
tion acute coronary syndrome; STEMI, ST-segment–elevation
myocardial infarction.
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PR vs PE PE vs CP PR vs CP
Age, y 65.311.9 62.812.3 69.99.2 <0.0001 0.0009 <0.001 <0.0001
Men 478 (78.8) 380 (79.7) 121 (77.1) 0.78
Presentation <0.0001 <0.0001 0.36 <0.0001
STEMI 385 (63.4) 193 (40.5) 70 (44.6)
NSTE-ACS 222 (36.6) 284 (59.5) 87 (55.4)
Hypertension 401 (66.1) 283 (59.3) 123 (78.3) <0.0001 0.03 <0.0001 0.003
Dyslipidemia 442 (72.8) 329 (69.0) 114 (72.6) 0.35
Diabetes mellitus 201 (33.1) 130 (27.3) 64 (40.8) 0.004 0.04 0.001 0.07
Current smoker 254 (42.0) 196 (41.4) 39 (25.0) 0.0003 0.86 0.0002 0.0001
Past smoker 106 (17.5) 106 (22.4) 52 (33.3) <0.0001 0.05 0.006 <0.0001
Current+past smoker 360 (59.5) 302 (63.9) 91 (58.3) 0.27   
Previous MI 45 (7.4) 30 (6.3) 19 (12.1) 0.06
Previous PCI 56 (9.2) 40 (8.4) 23 (14.7) 0.06
Family history 88 (14.5) 85 (17.8) 32 (20.4) 0.13
CKD 113 (18.6) 52 (10.9) 51 (32.5) <0.0001 0.0004 <0.0001 0.0002
Laboratory data
WBC, /lL 96753386 90763270 87173500 0.001 0.004 0.26 0.001
Hemoglobin, g/dL 14.01.8 14.21.7 13.32.2 <0.0001 0.03 <0.0001 0.003
LDL-C, mg/dL 12842 12141 10841 <0.0001 0.005 0.001 <0.0001
Creatinine, mg/dL 0.970.79 0.900.72 1.652.41 <0.0001 0.16 0.0003 0.0008
hs-CRP, mg/dL 0.842.25 0.450.95 0.921.95 0.003 0.0004 0.003 0.05
CPK, IU/L 518928 371652 438935 0.03 0.004 0.47 0.13
Medication at admission
Aspirin 92 (19.7) 75 (20.3) 54 (37.2) <0.0001 0.84 <0.0001 <0.0001
P2Y12 inhibitor 38 (8.1) 41 (11.1) 27 (18.5) 0.002 0.14 0.03 0.0003
Statin 115 (24.6) 82 (22.2) 59 (40.7) <0.0001 0.41 <0.0001 0.0002
ACE-I/ARB 134 (28.6) 105 (28.3) 70 (48.0) <0.0001 0.92 <0.0001 <0.0001
b-blocker 63 (13.5) 60 (16.2) 39 (26.7) 0.0008 0.27 0.006 0.0002
Angiographic data
Lesion location 0.0002 0.0002 0.77 0.007
LAD 278 (45.8) 270 (56.6) 93 (59.2)
LCX 83 (13.7) 71 (14.9) 20 (12.7)
RCA 246 (40.5) 136 (28.5) 44 (28.0)
QCA
RVD, mm 2.970.70 2.860.70 2.870.74 0.04 0.02 0.70 0.02
MLD, mm 0.510.59 0.680.66 0.730.68 <0.0001 <0.0001 0.48 0.0005
Diameter stenosis (%) 83.218.4 77.020.2 75.420.8 <0.0001 <0.0001 0.43 <0.0001
Lesion length, mm 16.17.8 15.16.5 17.88.5 0.0004 0.02 0.0005 0.02
TIMI flow grade 0 to 1 242 (39.9) 119 (25.0) 37 (23.6) <0.0001 <0.0001 0.73 0.0002
Multivessel disease 232 (39.1) 149 (32.5) 78 (52.0) <0.0001 0.03 <0.0001 0.004
Continued
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parameters associated with plaque erosion. When all 5
parameters are present in a patient with NSTE-ACS, the
probability of plaque erosion increased to 73.1% (Figure 3).
When all 5 conditions were present in NSTE-ACS patients, the
odds ratio of plaque erosion was 3.40 (95% CI: 1.39–8.29,
P=0.007). A 1000 bootstrap-samples based estimation for the
probability of plaque erosion was conducted. The estimated
probabilities are within the initial estimates (Table S5).
Discussion
This is an international collaborative work that includes
>1200 patients with both STEMI and NSTE-ACS from 11
institutions in 6 countries to identify parameters associated
with plaque erosion. Plaque erosion was more frequent in
NSTE-ACS than in STEMI. Five parameters associated with
plaque erosion are identified: (1) Age <68 years, (2) anterior
ischemia, (3) no diabetes mellitus, (4) hemoglobin >15.0 g/
dL, and (5) normal renal function. When all these 5 conditions
are present in a patient with NSTE-ACS, the probability of
plaque erosion increases up to 73%.
Traditional Coronary Risk Factors in Plaque
Erosion
Some of the conventional risk factors for coronary artery
disease (older age, diabetes mellitus, dyslipidemia, chronic
kidney disease, hypertension) were less frequent in plaque
erosion, while younger age, no diabetes mellitus, and normal
renal function were associated with plaque erosion in the
current study. In addition, high-sensitivity C-reactive protein









PR vs PE PE vs CP PR vs CP
Type B2/C lesion 483 (79.6) 286 (60.0) 122 (77.7) <0.0001 <0.0001 <0.0001 0.61
OCT findings
Lipid-rich plaque 554 (91.3) 178 (37.3) 24 (15.3) <0.0001 <0.0001 <0.0001 <0.0001
TCFA 373 (61.5) 33 (6.9) 5 (3.2) <0.0001 <0.0001 0.09 <0.0001
Macrophage 486 (80.1) 263 (55.1) 43 (27.4) <0.0001 <0.0001 <0.0001 <0.0001
Calcification 231 (38.1) 160 (33.5) 158 (100) <0.0001 0.12 <0.0001 <0.0001
Minimum flow area, mm2 1.381.01 1.431.34 1.781.43 <0.0001 0.51 <0.0001 <0.0001
Minimum FCT, lm 6933 12165 11581 <0.0001 <0.0001 0.18 0.0007
Max lipid arc, degree 30864 27680 27378 <0.0001 <0.0001 0.84 0.03
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; CKD, chronic kidney disease; CP, calcified plaque; CPK,
creatine phosphokinase; FCT, fibrous cap thickness; hs-CRP, high-sensitivity C-reactive protein; LAD, left anterior descending artery; LCX, left circumflex artery; LDL-C, low-density
lipoprotein cholesterol; MI, myocardial infarction; MLD, minimum lumen diameter; NSTE-ACS, non–ST-segment–elevation acute coronary syndrome; PCI, percutaneous coronary
intervention; PE, plaque erosion; QCA, quantitative coronary angiography; PR, plaque rupture; RCA, right coronary artery; RVD, reference vessel diameter; STEMI, ST-segment–elevation
myocardial infarction; TCFA, thin-cap fibroatheroma; TIMI, Thrombolysis in Myocardial Infarction; WBC, white blood cell count.
*P<0.017 was considered significant.
Table 2. Clinical and Laboratory Predictors of Plaque Erosion
Variables
Unadjusted Adjusted
OR 95% CI P Value OR 95% CI P Value
Age <68 y 1.65 1.31 to 2.08 <0.0001 1.56 1.16 to 2.09 0.003
Anterior ischemia 1.38 1.10 to 1.74 0.006 1.41 1.06 to 1.86 0.02
No DM 1.42 1.10 to 1.82 0.006 1.47 1.08 to 2.01 0.01
Hemoglobin >15.0 g/dL 1.67 1.25 to 2.34 0.0006 1.48 1.09 to 2.01 0.01
Normal renal function 2.23 1.60 to 3.13 <0.0001 1.97 1.32 to 2.95 0.0009
No hypertension 1.50 1.18 to 1.90 0.0009 1.26 0.94 to 1.68 0.13
Statin 0.72 0.53 to 0.97 0.03 1.21 0.88 to 1.69 0.24
DM indicates diabetes mellitus; OR, odds ratio.
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the erosion patients. OCT analysis also demonstrated
significantly lower levels of plaque vulnerability (lipid-rich
plaque, thin-cap fibroatheroma, and macrophage). Taken
together, all these data suggest that plaque erosion has a
distinctly different pathobiology compared with plaque
rupture. Previous pathology studies reported that the
characteristics of plaque erosion, which include thrombus
over less atherosclerotic and less vulnerable lesions without
disruption of plaque structure and absence of endothelial cell
layer.3,17,18 However, the underlying mechanism of local
thrombosis remains unclear. A “2-hit scheme” was proposed
for the pathogenesis of plaque erosion.19,20 The “first-hit” is
chronic endothelial activation, propensity to slough, and
impaired ability to repair the damaged endothelium. Dis-
turbed flow was suspected to be the etiology, leading to
activation of endothelial Toll-like receptor 2. The “second-hit”
is recruitment of neutrophils via Toll-like receptor 2 and
subsequent formation of neutrophil extracellular traps, as
well as local production of chemo-attractants, thrombin, and
fibrin, which further entrap platelets and lead to thrombus
formation. This process is independent from pan-vascular
chronic inflammation that lead to atherosclerosis, therefore
plaque erosion can occur in younger patients with less
atherosclerosis.
Local Fluid Dynamics in Plaque Erosion
Interestingly, high hemoglobin level was found to be a strong
factor associated with plaque erosion. The changes of
hemoglobin level over time were not collected. Therefore, a
causal relationship cannot be established. However, several
studies reported hemoconcentration was the risk factor for
myocardial infarction.21 Hemoconcentration can increase
blood viscosity, resulting in elevation of local endothelial
shear stress. High shear condition activates both platelets
and coagulation factors.22,23 It was recently reported that
high endothelial shear stress was associated with the
thrombus in plaque erosion patients.24 Therefore, high
hemoglobin levels attributable to several systemic condition
may contribute to formation of occlusive thrombus in plaque
erosion. In addition, plaque erosion was more frequently
observed in the left anterior descending artery with anterior
ischemia than in the right coronary artery or circumflex. The
left anterior descending artery has more side branches than
other vessels. The presence of side branches affects the
conditions of local flow dynamics and distribution of endothe-
lial shear stress,25 which may play a key role in pathogenesis
of erosion.
STEMI and NSTE-ACS in Plaque Erosion
In the current study, 41% of plaque erosion patients
presented with STEMI and the remaining 59% of patients
presented with NSTE-ACS. Because of relatively preserved
vascular structure, plaque erosion may be prone to develop
non-occlusive thrombus or occlusive thrombus that may be
easily embolized distally. Several differences were noted
between these 2 groups: the erosion patients with STEMI
were more frequently smokers, had higher levels of serum
low-density lipoproteins, and took fewer medications on
admission than those with NSTE-ACS (Table S4). The
medications might have protected these patients from
persistent occlusive thrombus formation. In addition, the
smoking rate was significantly higher in plaque erosion
patients with STEMI. Several previous studies reported that
plaque erosion is associated with smoking.11,17,18 Smoking
promotes activation of both platelets and clotting fac-
tors.26,27 In addition, smoking causes endothelial damage28
as well as activation of Rho-kinase,29 which leads to vascular
hyperconstriction or vasospasm.
Clinical Significance of Predictors of Plaque
Erosion
This study included only patients who had OCT imaging,
therefore the result might not represent a general ACS
population. Taken together, however, the current study
suggests that, contrary to atherosclerotic lesions with
underlying chronic inflammatory processes, plaque erosion
might be the result of a combination of several “non-
traditional” factors including endothelial, vasomotion, fluid
dynamic, and systemic effects (Figure 4). Thus, the optimal
management for plaque erosion might be different from the
traditional treatment of plaque rupture. In the EROSION
(Effective Anti-Thrombotic Therapy Without Stenting: Intravas-
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Figure 3. Probability of plaque erosion. When all 5 parameters
are present in a patient with non–ST-segment–elevation acute
coronary syndrome, the probability of plaque erosion increased to
73.1%. When a patient with non–ST-segment–elevation acute
coronary syndrome has all 5 parameters, the odd ratio increases
to 3.40. DM indicates diabetes mellitus.
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Plaque Erosion) study, we demonstrated the feasibility and
safety of anti-thrombotic therapy without stenting in patients
with ACS caused by plaque erosion.6 We also reported a further
decrease in thrombus volume between 1 month and 1 year,
and a majority of patients with plaque erosion who were
managed with aspirin and ticagrelor without stenting remained
free of major adverse cardiac events up to 1 year.30 These
results suggest that a tailored approach based on the under-
lying pathobiology of ACS may be warranted. Ultimately,
whereas emergency invasive procedure with primary percuta-
neous coronary intervention is the standard of care for the
patients with STEMI, those with NSTE-ACS can often be
stabilized with anti-thrombotic therapy. Identification of a
subset of NSTE-ACS patients with high probability of plaque
erosion may facilitate an early triage of the patients and provide
an opportunity for tailored therapy.
A different approach will be needed not only for the
management after ACS, but also for prevention. In the EROSION
study, all patients were treated with dual anti-platelet therapy
for 1 year.30,31 Anti-thrombotic therapy should be themainstay
for plaque erosion patients without stenting. However, optimal
duration/choice ofmedications remains unknown. The restora-
tion of endothelial function should also be considered.
Cessation of smoking could be particularly important.
Study Limitations
This study has several limitations. First, only patients who had
undergone anOCT procedurewere included, and the decision to
perform OCT was left at the discretion of each operator.
Therefore, true denominator is unknown and the inherent
selection bias cannot be excluded. However, investigators in
participating institutions have extensive experience with OCT
and OCT is routinely being performed in almost all comers.
Second, since this was not a prospective study, there is the
possibility of unmeasured confounders. Third, although data
were collected from 11 institutions including 3 in Europe and 1
in the United States, the majority of patients were Asians.
Fourth, no biomarkers were measured. If biomarkers specific
for plaque erosion are discovered, it may significantly increase
the accuracy of non-invasive diagnosis of plaque erosion. Fifth,
it can indeed be difficult tomake a diagnosis of plaque erosion in
the presence of large thrombus burden. Aspiration thrombec-
tomy was allowed, but the cases with balloon angioplasty were
excluded to avoid iatrogenic damage to the vessel wall including
plaque rupture. The majority of plaque ruptures are associated
with superficial lipid and an emptied cavity. Those cases with
large residual thrombus after thrombectomy or the cases with
unclear diagnosis were excluded.
Conclusions
Plaque erosion was more frequent in NSTE-ACS than in
STEMI. Five parameters associated with plaque erosion have
been identified; younger age, anterior ischemia, no diabetes
mellitus, normal renal function, and higher hemoglobin levels.
These parameters might be useful for identification of patients
with plaque erosion for possible tailored therapy based on
underlying pathobiology of ACS. The results of this explora-
tory analysis need to be confirmed in large scale prospective
clinical studies.
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Acute coronary syndrome (ACS) includes ST-segment-elevation myocardial infarction (STEMI), non-
ST-segment-elevation myocardial infarction (NSTEMI), and unstable angina pectoris (UAP). Non-ST-
segment-elevation ACS (NSTE-ACS) includes NSTEMI and UAP. STEMI is defined as continuous 
chest pain that lasts > 30 min., arrival at the hospital within 12 hours from the onset of symptoms, ST-
segment-elevation > 0.1 mV in ≧ 2 contiguous leads or new left bundle-branch block on the 12-lead 
electrocardiogram (ECG), and elevated cardiac markers (creatine kinase-myocardial band or troponin 
T/I). NSTEMI is defined as ischemic symptoms in the absence of ST-segment elevation on the ECG 
with elevated cardiac markers. UAP is defined as having newly developed/accelerating chest symptoms 
on exertion or rest angina within 2 weeks. Chronic kidney disease (CKD) is defined as eGFR < 
60ml/min/1.73m2 for ≧3 months. Normal renal function is defined as no history of CKD and eGFR > 
60ml/min at admission. The culprit lesion was determined based on angiographic findings, ECG 
changes, and/or left ventricular wall motion abnormalities. Anterior ischemia is defined as culprit lesion 
located in left anterior descending artery. 
 
 
OCT image analysis 
<Tissue characterization of underlying plaque> 
Tissue characterization of underlying plaque was performed using the previously established criteria 1,2. 
Plaques were classified into 2 categories: (1) Fibrous Plaque (homogeneous and high-backscattering 
region) or (2) Lipid Plaque (low signal region with a diffuse border). Lipid-rich plaque was defined as a 
plaque with lipid arc > 90 degrees. For each lipid plaque, the thinnest fibrous cap thickness and the 
maximal arc of lipid were measured. A thin-cap fibroatheroma (TCFA) was defined as plaque with a 
lipid arc >90 degrees and the thinnest part of the fibrous cap < 65 µm. Macrophage accumulations were 
defined as signal-rich, distinct or confluent punctuate regions with heterogeneous backward shadows. 
Calcification was recorded as well-delineated, low backscattering heterogeneous regions. Minimal flow 
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Participating sites Country Number of patients 
Tsuchiura Kyodo General Hospital Japan 318 
Nara Medical University Hospital Japan 257 
The Chinese University of Hong Kong Hong Kong 193 
Nippon Medical Chiba Hokusoh Hospital Japan 188 
Massachusetts General Hospital US 181 
Catholic University of the Sacred Heart Italy 148 
Hirosaki University Hospital Japan 130 
University of Giessen Germany 83 
University Hospitals Leuven Belgium 74 
Kameda Medical Center Japan 64 
Kitasato University Hospital Japan 63 
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Table S2. Patient characteristics (Erosion vs Non-erosion).  
 




Age, years 62.8 ± 12.3 66.2 ± 11.5 < 0.001 




  STEMI 193 (40.5) 455 (59.5)   
  NSTE-ACS 284 (59.5) 309 (40.5)   
Hypertension 283 (59.3) 524 (68.6) < 0.001 
Dyslipidemia 329 (69.0) 556 (72.8) 0.15 
Diabetes Mellitus 130 (27.3) 265 (34.7) 0.006 
Current smoker 196 (41.4) 293 (38.5) 0.31 
Past smoker 106 (22.4) 158 (20.8) 0.49 
Current + past smoker 302 (63.9) 451 (59.3) 0.11 
Previous MI 30 (6.3) 64 (8.4) 0.18 
Previous PCI 40 (8.4) 79 (10.3) 0.26 
Family history of CAD 85 (17.8) 120 (15.7) 0.33 
CKD 52 (10.9) 164 (21.5) < 0.001 
Laboratory data 
   
 WBC, /μL 9076 ± 3270 9493 ± 3426 0.02 
 Hb, g/dL 14.2 ± 1.7 13.8 ± 1.9 0.002 
 LDL, mg/dL 121 ± 41 124 ± 43 0.26 
 Creatine, mg/dL 0.90 ± 0.72 1.11 ± 1.32 0.008 
 hs-CRP, mg/dL 0.45 ± 0.95 0.86 ± 2.20 0.01 
 CPK, IU/L 371 ± 652 504 ± 929 0.001 
Medication at admission 
   
 Aspirin 75 (20.3) 146 (23.9) 0.19 
 P2Y12 inhibitor 41 (11.1) 65 (10.5) 0.80 
 Statin 82 (22.2) 174 (28.4) 0.03 
 ACE-I/ARB 105 (28.3) 204 (33.2) 0.11 
 β-blocker 60 (16.2) 102 (16.6) 0.86 
 
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CAD = coronary 
artery disease; CKD = chronic kidney disease; CPK = creatine phosphokinase; Hb = hemoglobin; hs-CRP = 
high-sensitivity C-reactive protein; LDL-C = low- density lipoprotein cholesterol; MI = myocardial infarction; 
NSTE-ACS = non-ST-segment-elevation myocardial acute coronary syndrome; PCI = percutaneous coronary 
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N=607 N=477 N=157 All   PR vs PE PE vs CP PR vs CP 
Procedure detail 
  
      
 Thrombectomy 307 (64.9) 151 (41.8) 50 (43.5) < 0.001   < 0.001 0.76 < 0.001 
 Stenting 593 (97.7) 441 (92.5) 155 (98.7) < 0.001   < 0.001 0.004 0.42 
  Number of stent(s) 1.2 ± 0.5 1.1 ± 0.6 1.3 ± 0.6 0.01   0.15 0.04 0.02 
  Stent diameter, mm 3.2 ± 0.5 3.1 ± 0.4 3.0 ± 0.4 0.004   0.08 0.06 0.002 
  Total stent length, mm 28.0 ± 14.1 27.2 ± 15.1 30.0 ± 15.1 0.25      
Post procedure     
 
     
 Peak CPK, IU/L 2078 ± 2396 1264 ± 1901 1527 ± 1987 < 0.001   < 0.001 0.12 0.002 
 
        
In-hospital death 9 (1.5) 3 (0.6) 0 0.15      
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in erosion p 
 N=193 N=284  
Age, years 62.5 ± 11.7 63.0 ± 12.8 0.62 
Male 159 (82.4) 221 (77.8) 0.22 
Hypertension 104 (53.9) 179 (63.0) 0.05 
Dyslipidemia 139 (72.0) 190 (66.9) 0.24 
Diabetes Mellitus 47 (24.4) 83 (29.2) 0.24 
Current smoker 83 (43.7) 113 (39.9) 0.42 
Past smoker 54 (28.4) 52 (18.4) 0.01 
Current + past smoker 137 (72.1) 165 (58.3) 0.002 
Previous MI 7 (3.6) 23 (8.1) 0.05 
Previous PCI 7 (3.6) 33 (11.6) 0.002 
Family history of CAD 36 (18.7) 49 (17.3) 0.70 
CKD 20 (10.4) 32 (11.3) 0.76 
Laboratory data    
 WBC, /μL 10250 ± 3486 8221 ± 2817 < 0.001 
 Hb, g/dL 14.4 ± 1.8 14.1 ± 1.6 0.13 
 LDL-C, mg/dL 127 ± 39 117 ± 42 0.01 
 Creatinine, mg/dL 0.91 ± 0.67 0.90 ± 0.76 0.82 
 hs-CRP, mg/dL 0.32 ± 0.57 0.54 ± 1.15 0.01 
 CPK, IU/L 572 ± 878 219 ± 328 < 0.001 
Medication at admission    
 Aspirin 21 (11.9) 54 (28.0) < 0.001 
 P2Y12 inhibitor 9 (5.1) 32 (16.5) < 0.001 
 Statin 20 (11.3) 62 (32.1) < 0.001 
 ACE-I/ARB 41 (23.2) 64 (33.0) 0.04 
 β-blocker 17 (9.6) 43 (22.3) 0.002 
ACE-I = angiotensin-converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CAD = 
coronary artery disease; CPK = creatine phosphokinase; Hb = hemoglobin; hs-CRP = high-sensitivity C-
reactive protein; LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; NSTE-ACS 
= non-ST-segment-elevation myocardial acute coronary syndrome; PCI = percutaneous coronary 
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Table S5. Estimation for the probability of plaque erosion. 
 
    95%CI 
  
Predicted Percentage 




Present all 5 factors  Plaque erosion 73.1 8.8 53.8 88.5 
 Others 26.9 8.8 11.5 46.2 
Present 3 factors Plaque erosion 62.7 4.5 54 72.2 
(Age, Anterior ischemia, NoDM) Others 37.3 4.5 27.8 46 
Present 2 factors Plaque erosion 56.7 3.6 49.7 63.5 
(Age, Anterior ischemia) Others 43.3 3.6 36.5 50.3 
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Among 1699 ACS patients, 458 patients were excluded, and 1241 patients were included in the final analysis. 
ACS = acute coronary syndromes; ISR = in-stent restenosis; OCT = optical coherence tomography; PCI = 
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